17.2 C
Brisbane
Saturday, September 19, 2020

Johnson & Johnson partners with BARDA to fund $1 billion in COVID-19 vaccine research

Must read

FACEBOOK WATCH: WATER CRISIS HIT JUBA

Water tankers in Juba are on strike a move staged to hike water prices. A normal barrel of water used to...

South Sudan teachers not paid for 13 months, set off strikes in Jonglei State

High school teachers in Jonglei State are protesting in demand of about 19 million South Sudanese pounds that should have been paid...

Rwanda: Tanzania, Rwanda to Resolve Cross Border Trade Hurdles

TANZANIA and Rwanda have agreed to meet at the end of this month to discuss and address various bottlenecks that impede smooth...

Progress on South Sudan peace agreement ‘limps along’

Progress on implementing the South Sudan peace agreement is halting partially due to the coronavirus pandemic, according to a special representative of...

TECHCRUNCH 31 MAR 2020

Pharmaceutical giant Johnson & Johnson is partnering with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to fund over $1 billion in COVID-19 vaccine and antiviral treatment research and development, the company said on Monday.

The partnership is an expansion of an existing agreement between BARDA and J&J’s Janssen Pharmaceutical Companies division.

With the agreement, the company is setting a goal of providing a global supply of more than one billion doses of the vaccine, which J&J expects to have in clinical trials by September 2020 at the latest. The first batches of the vaccine may be available for emergency use by early 2021, the company said.

BARDA’s partnership with J&J encompasses research and development of potential antiviral treatments in addition to the work that’s being done to develop a vaccine for the disease. Those efforts include development work J&J and BARDA are conducting with the Rega Institute for Medical Research in Belgium.

J&J said it had also committed to expanding its global manufacturing capacity, both in the U.S. and overseas.

That additional production ability will help the company bring an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use, the company said.

Working with teams at Beth Israel Deaconess Medical Center, a part of the Harvard Medical School, Janssen Pharmaceuticals began its research into potential vaccine candidates back in January. Those candidates were tested at several academic institutions, the company said, which led to the identification of a lead COVID-19 vaccine candidate — and two potential back-ups.

Last week, Moderna Health, another pharmaceutical company working on a vaccine, said that it could have an experimental treatment available to healthcare workers as soon as the fall.

The Moderna vaccine uses messenger RNA, rather than doses of the COVID-19 virus itself, to inoculate against the disease. The use of mRNA means that the inoculation doesn’t expose recipients to the disease itself, so they’re not at risk of contracting the disease.

Last Monday, Moderna made the vaccine available to volunteer participants as part of the company’s Phase 1 clinical trials conducted in Washington state.

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article

FACEBOOK WATCH: WATER CRISIS HIT JUBA

Water tankers in Juba are on strike a move staged to hike water prices. A normal barrel of water used to...

South Sudan teachers not paid for 13 months, set off strikes in Jonglei State

High school teachers in Jonglei State are protesting in demand of about 19 million South Sudanese pounds that should have been paid...

Rwanda: Tanzania, Rwanda to Resolve Cross Border Trade Hurdles

TANZANIA and Rwanda have agreed to meet at the end of this month to discuss and address various bottlenecks that impede smooth...

Progress on South Sudan peace agreement ‘limps along’

Progress on implementing the South Sudan peace agreement is halting partially due to the coronavirus pandemic, according to a special representative of...

Burundi: New Government, but no progress insight on the human rights front

Following the 2020 presidential, legislative and local elections, the fifteen-year presidency of Pierre Nkurunziza came to a close and a new era...